162 related articles for article (PubMed ID: 36929466)
1. ACADL suppresses PD-L1 expression to prevent cancer immune evasion by targeting Hippo/YAP signaling in lung adenocarcinoma.
Li L; Wang LL; Wang TL; Zheng FM
Med Oncol; 2023 Mar; 40(4):118. PubMed ID: 36929466
[TBL] [Abstract][Full Text] [Related]
2. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
3. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
4. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.
Kim MH; Kim CG; Kim SK; Shin SJ; Choe EA; Park SH; Shin EC; Kim J
Cancer Immunol Res; 2018 Mar; 6(3):255-266. PubMed ID: 29382670
[TBL] [Abstract][Full Text] [Related]
5. m
Wu J; Yi T; Zhuo C; Wang D; Zhang M; Hu R; Wu D; Hou G; Xing Y
J Cell Physiol; 2024 May; 239(5):e31220. PubMed ID: 38372068
[TBL] [Abstract][Full Text] [Related]
6. ACADL plays a tumor-suppressor role by targeting Hippo/YAP signaling in hepatocellular carcinoma.
Zhao X; Qin W; Jiang Y; Yang Z; Yuan B; Dai R; Shen H; Chen Y; Fu J; Wang H
NPJ Precis Oncol; 2020; 4():7. PubMed ID: 32219176
[TBL] [Abstract][Full Text] [Related]
7. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
[TBL] [Abstract][Full Text] [Related]
8. Bulk and single-cell transcriptome profiling reveal extracellular matrix mechanical regulation of lipid metabolism reprograming through YAP/TEAD4/ACADL axis in hepatocellular carcinoma.
Cai J; Chen T; Jiang Z; Yan J; Ye Z; Ruan Y; Tao L; Shen Z; Liang X; Wang Y; Xu J; Cai X
Int J Biol Sci; 2023; 19(7):2114-2131. PubMed ID: 37151879
[TBL] [Abstract][Full Text] [Related]
9. FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.
Lu M; Wang K; Ji W; Yu Y; Li Z; Xia W; Lu S
Cell Immunol; 2022 Sep; 379():104577. PubMed ID: 35870429
[TBL] [Abstract][Full Text] [Related]
10. Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma.
Zhang X; Yu K; Ma L; Qian Z; Tian X; Miao Y; Niu Y; Xu X; Guo S; Yang Y; Wang Z; Xue X; Gu C; Fang W; Sun J; Yu Y; Wang J
Theranostics; 2021; 11(12):5650-5674. PubMed ID: 33897873
[No Abstract] [Full Text] [Related]
11. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
Wu A; Wu Q; Deng Y; Liu Y; Lu J; Liu L; Li X; Liao C; Zhao B; Song H
EMBO J; 2019 Jan; 38(1):. PubMed ID: 30396996
[TBL] [Abstract][Full Text] [Related]
12. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
Zhu J; Li Y; Lv X
Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
[TBL] [Abstract][Full Text] [Related]
15. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.
Yan R; Li J; Zhou Y; Yao L; Sun R; Xu Y; Ge Y; An G
Life Sci; 2020 Jan; 241():117150. PubMed ID: 31837335
[TBL] [Abstract][Full Text] [Related]
17. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
[TBL] [Abstract][Full Text] [Related]
18. Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation.
Ni W; Mo H; Liu Y; Xu Y; Qin C; Zhou Y; Li Y; Li Y; Zhou A; Yao S; Zhou R; Huo J; Che L; Li J
Mol Ther; 2021 Oct; 29(10):2995-3010. PubMed ID: 33992804
[TBL] [Abstract][Full Text] [Related]
19. RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer.
Yang H; Xue M; Su P; Zhou Y; Li X; Li Z; Xia Y; Zhang C; Fu M; Zheng X; Luo G; Wei T; Wang X; Ding Y; Zhu J; Zhuang T
J Exp Clin Cancer Res; 2022 Dec; 41(1):364. PubMed ID: 36581998
[TBL] [Abstract][Full Text] [Related]
20. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]